What is Concert Genetics (fka NextGxDX)?
Concert Genetics operates as a software and managed services provider, building the essential digital infrastructure for the effective management of genetic testing and the advancement of precision medicine. The company's capabilities are built upon a proprietary database of the U.S. clinical genetic testing market, complemented by market-leading expertise and a robust technology platform. This platform facilitates streamlined genetic test ordering, results management, coding, coverage verification, and payment integrity, addressing critical needs within the healthcare ecosystem.
How much funding has Concert Genetics (fka NextGxDX) raised?
Concert Genetics (fka NextGxDX) has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Concert Genetics (fka NextGxDX)
PPP
Public-Private Partnership
What's next for Concert Genetics (fka NextGxDX)?
The substantial capital infusion, particularly in this large-scale late-stage funding context, positions Concert Genetics for accelerated growth and market expansion. This strategic backing is expected to fuel further development of its digital infrastructure, enhance its proprietary database, and broaden its service offerings. The company is poised to solidify its role as a key enabler of efficient and reliable genetic testing management, driving greater adoption of precision medicine solutions across the healthcare industry.
See full Concert Genetics (fka NextGxDX) company page
